Autologous stem cell transplant for early relapsed/refractory Hodgkin lymphoma: Results from two transplant centres

Stephen D. Smith, Craig H. Moskowitz, Robert Dean, Brad Pohlman, Ronald Sobecks, Edward Copelan, Steven Andresen, Brian Bolwell, Jocelyn C. Maragulia, Jill M. Vanak, John Sweetenham, Alison J. Moskowitz

Research output: Contribution to journalArticlepeer-review

35 Scopus citations


Prior series have demonstrated that early relapsed (within 1year) or refractory Hodgkin lymphoma (HL) is associated with poor prognosis. To determine the outcome for patients with early relapsed/refractory HL in the modern era, we combined data from two large transplant centres, Cleveland Clinic Taussig Cancer Institute (CCTCI) and Memorial Sloan-Kettering Cancer Center (MSKCC), and analysed consecutive patients transplanted for relapsed/refractory HL following induction failure or remission durations of <1year. Two hundred and fourteen patients were analysed and the event-free survival (EFS) and overall survival (OS) at 6years for all patients were 45% and 55%, respectively. Factors significant for prognosis in multivariate analysis were extranodal disease and bulky disease (≥5cm). Patients with 0, 1, or 2 risk factors achieved 6year EFS of 65%, 47%, and 24% and 6year OS of 81%, 55%, and 27%, respectively. Patients with the sole risk factor of early relapsed/refractory disease achieved good outcomes in this large series; however the presence of bulk and/or extranodal disease significantly reduced EFS and OS. Patients with these additional risk factors are best suited for clinical trials investigating novel salvage regimens and post-transplant maintenance strategies.

Original languageEnglish (US)
Pages (from-to)358-363
Number of pages6
JournalBritish Journal of Haematology
Issue number3
StatePublished - May 2011
Externally publishedYes


  • Hodgkin lymphoma
  • Refractory
  • Relapse
  • Stem cell transplantation

ASJC Scopus subject areas

  • Hematology


Dive into the research topics of 'Autologous stem cell transplant for early relapsed/refractory Hodgkin lymphoma: Results from two transplant centres'. Together they form a unique fingerprint.

Cite this